Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China.
Int J Biol Sci. 2021 Jan 1;17(1):220-235. doi: 10.7150/ijbs.50730. eCollection 2021.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Increasing studies showed that long non-coding RNAs (lncRNAs), a novel class of RNAs that are greater than 200 nucleotides in length but lack the ability to encode proteins, exert crucial roles in the occurrence and progression of HCC. LncRNAs promote the proliferation, migration, invasion, autophagy, and apoptosis of tumor cells by regulating downstream target gene expression and cancer-related signaling pathways. Meanwhile, lncRNA can be used as biomarkers to predict the efficacy of HCC treatment strategies, such as surgery, radiotherapy, chemotherapy, and immunotherapy, and as a potential individualized tool for HCC diagnosis and treatment. In this review, we overview up-to-date findings on lncRNAs as potential biomarkers for HCC surgery, radiotherapy, chemotherapy resistance, target therapy, and immunotherapy, and discuss the potential clinical application of lncRNA as tools for HCC diagnosis and treatment.
肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一。越来越多的研究表明,长非编码 RNA(lncRNA)是一类新型的 RNA,长度大于 200 个核苷酸但缺乏编码蛋白质的能力,在 HCC 的发生和进展中发挥着关键作用。lncRNA 通过调节下游靶基因表达和癌症相关信号通路,促进肿瘤细胞的增殖、迁移、侵袭、自噬和凋亡。同时,lncRNA 可以作为生物标志物来预测 HCC 治疗策略(如手术、放疗、化疗和免疫治疗)的疗效,并作为 HCC 诊断和治疗的潜在个体化工具。在这篇综述中,我们概述了 lncRNA 作为 HCC 手术、放疗、化疗耐药、靶向治疗和免疫治疗的潜在生物标志物的最新研究结果,并讨论了 lncRNA 作为 HCC 诊断和治疗工具的潜在临床应用。